Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.44 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.44 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665919 | 0.80 | MEN1 (0.44) | TSHRALDH1A1TDP1CYP3A4HPGD | |
| SCHEMBL8286290 | 0.78 | TSHR (0.41) | TSHRALDH1A1TDP1CYP3A4HPGD | |
| SCHEMBL2681533 | 0.75 | VCAM1 (0.44) | TSHRALDH1A1TDP1CYP3A4HPGD | |
| SCHEMBL1456043 | 0.74 | DAO (0.55) | TSHRDAOGPR35VCAM1 | |
| SCHEMBL10201532 | 0.74 | USP7 (0.42) | TSHRALDH1A1CYP3A4DAOMAPK1 | |
| SCHEMBL1938624 | 0.74 | VCAM1 (0.42) | TSHRALDH1A1TDP1CYP3A4HPGD | |
| SCHEMBL14441148 | 0.74 | USP7 (0.41) | TSHRALDH1A1TDP1CYP3A4HPGD | |
| SCHEMBL2681454 | 0.72 | USP7 (0.58) | CYP3A4DAOGPR35VCAM1 | |
| SCHEMBL1185703 | 0.72 | VCAM1 (0.49) | TSHRALDH1A1TDP1CYP3A4HPGD | |
| SCHEMBL4859459 | 0.72 | GPR35 (0.42) | TSHRALDH1A1TDP1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053410-A1 | SUBSTITUTED HETEROARYL 2',3',7',7A'-TETRAHYDROSPIRO[PYRROLE-3,6'-PYRROLO[1,2-C]IMIDAZOLE]-1',2(1H,5'H)-DIONE | BARTKOVITZ DAVID JOSEPH (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2012022707-A1 | SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | BARTKOVITZ DAVID JOSEPH (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | BARTKOVITZ DAVID JOSEPH (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053410-A1 | SUBSTITUTED HETEROARYL 2',3',7',7A'-TETRAHYDROSPIRO[PYRROLE-3,6'-PYRROLO[1,2-C]IMIDAZOLE]-1',2(1H,5'H)-DIONE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PYCR1, DHPS | TSHR 1079/4885ALDH1A1 303/4885TDP1 590/4885 |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | MDM2, TP53, RB1 | TSHR 1288/4885ALDH1A1 1065/4885TDP1 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.